|
1
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar
|
|
2
|
Dimou A and Papadimitrakopoulou V:
Non-Small cell lung cancer beyond biomarkers: The evolving
landscape of clinical trial design. J Pers Med. 4:386–401. 2014.
View Article : Google Scholar :
|
|
3
|
Chouaid C, Crequit P, Borget I and
Vergnenegre A: Economic evaluation of first-line and maintenance
treatments for advanced non-small cell lung cancer: A systematic
review. Clinicoecon Outcomes Res. 7:9–15. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moss EG: MicroRNAs: Hidden in the genome.
Curr Biol. 12:R138–R140. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Choi E, Choi E and Hwang KC: MicroRNAs as
novel regulators of stem cell fate. World J Stem Cells. 5:172–187.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lujambio A, Calin GA, Villanueva A, Ropero
S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso
MS, Faller WJ, et al: A microRNA DNA methylation signature for
human cancer metastasis. Proc Natl Acad Sci USA. 105:13556–13561.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ceppi P, Mudduluru G, Kumarswamy R, Rapa
I, Scagliotti GV, Papotti M and Allgayer H: Loss of miR-200c
expression induces an aggressive, invasive and chemoresistant
phenotype in non-small cell lung cancer. Mol Cancer Res.
8:1207–1216. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li J, Tan Q, Yan M, Liu L, Lin H, Zhao F,
Bao G, Kong H, Ge C, Zhang F, et al: miRNA-200c inhibits invasion
and metastasis of human non-small cell lung cancer by directly
targeting ubiquitin specific peptidase 25. Mol Cancer. 13:1662014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi L, Zhang S, Wu H, Zhang L, Dai X, Hu
J, Xue J, Liu T, Liang Y and Wu G: MiR-200c increases the
radiosensitivity of non-small-cell lung cancer cell line A549 by
targeting VEGF-VEGFR2 pathway. PLoS One. 8:e783442013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Remacle JE, Kraft H, Lerchner W, Wuytens
G, Collart C, Verschueren K, Smith JC and Huylebroeck D: New mode
of DNA binding of multi-zinc finger transcription factors: deltaEF1
family members bind with two hands to two target sites. EMBO J.
18:5073–5084. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nam EH, Lee Y, Park YK, Lee JW and Kim S:
ZEB2 upregulates integrin alpha5 expression through cooperation
with Sp1 to induce invasion during epithelial-mesenchymal
transition of human cancer cells. Carcinogenesis. 33:563–571. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
You J, Li Y, Fang N, Liu B, Zu L, Chang R,
Li X and Zhou Q: MiR-132 suppresses the migration and invasion of
lung cancer cells via targeting the EMT regulator ZEB2. PLoS One.
9:e918272014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
15
|
Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ,
Wang YK, Zeng F, Zhou JH and Zhang YK: High expression of serum
miR-21 and tumor miR-200c associated with poor prognosis in
patients with lung cancer. Med Oncol. 29:618–626. 2012. View Article : Google Scholar
|
|
16
|
Tejero R, Navarro A, Campayo M, Viñolas N,
Marrades RM, Cordeiro A, Ruíz-Martínez M, Santasusagna S, Molins L,
Ramirez J and Monzó M: miR-141 and miR-200c as markers of overall
survival in early stage non-small cell lung cancer adenocarcinoma.
PLoS One. 9:e1018992014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang X, Wang J, Qu S, Zhang H, Ruan B, Gao
Y, Ma B, Wang X, Wu N, Li X, et al: MicroRNA-200a suppresses
metastatic potential of side population cells in human
hepatocellular carcinoma by decreasing ZEB2. Oncotarget.
6:7918–7929. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou X, Wang Y, Shan B, Han J, Zhu H, Lv
Y, Fan X, Sang M, Liu XD and Liu W: The downregulation of
miR-200c/141 promotes ZEB1/2 expression and gastric cancer
progression. Med Oncol. 32:4282015. View Article : Google Scholar
|
|
19
|
Chen Z, Tang ZY, He Y, Liu LF, Li DJ and
Chen X: miRNA-205 is a candidate tumor suppressor that targets ZEB2
in renal cell carcinoma. Oncol Res Treat. 37:658–664. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guo F, Cogdell D, Hu L, Yang D, Sood AK,
Xue F and Zhang W: MiR-101 suppresses the epithelial-to-mesenchymal
transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol
Rep. 31:2021–2028. 2014.PubMed/NCBI
|
|
21
|
Qi S, Song Y, Peng Y, Wang H, Long H, Yu
X, Li Z, Fang L, Wu A, Luo W, et al: ZEB2 mediates multiple
pathways regulating cell proliferation, migration, invasion and
apoptosis in glioma. PLoS One. 7:e388422012. View Article : Google Scholar
|
|
22
|
Usova EV, Kopantseva MR, Kostina MB,
Van'kovich AN, Egorov VI and Kopantsev EP: Expression of the ZEB2
gene in pancreatic stromal cells in pancreatic ductal
adenocarcinoma, pancreatitis and normal state. Dokl Biol Sci.
448:61–64. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fang S, Zeng X, Zhu W, Tang R, Chao Y and
Guo L: Zinc finger E-box-binding homeobox 2 (ZEB2) regulated by
miR-200b contributes to multi-drug resistance of small cell lung
cancer. Exp Mol Pathol. 96:438–444. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
